Showing 231-240 of 7665 results for "".
- Man Vs. Machine: AI May Be as Reliable as Doctors for Diagnosing Skin Cancerhttps://practicaldermatology.com/news/man-vs-machine-ai-may-be-as-reliable-as-doctors-for-diagnosing-skin-cancer/2462088/Skin cancer diagnoses using artificial intelligence (AI) are as reliable as those made by medical experts, but doctors are clearly superior when it came to treatment decisions. These are the main takeaways from research looking at AI applications under realistic clinical conditions in two skin ca…
- Sciton Adds 1064nm Wavelength to mJOULE Platformhttps://practicaldermatology.com/news/sciton-adds-1064nm-wavelength-to-mjoule-platform/2462081/Sciton Inc. is expanding their mJOULE system to include ClearV and ClearSilk to treat vascular lesions and skin discoloration. "The combination of 1064 in the ClearV and ClearSilk delivery systems with the narrowband 532+ BBL filter replaces the need for all other vascular lasers in your practice.…
- Four Grants Awarded by the GW/Pfizer Global Medical Collaborative Grant Program to Establish Teledermatology Programs in Underserved Communities Across the UShttps://practicaldermatology.com/news/four-grants-awarded-by-the-gwpfizer-global-medical-collaborative-grant-program-to-establish-teledermatology-programs-in-underserved-communities-across-the-us/2462080/The George Washington University (GW) School of Medicine and Health Sciences (SMHS), in collaboration with Pfizer Global Medical Grants, announced the four institutions that will be awarded grants to implement GW’s Teledermatology clinic model in underserved areas across the United States. The re…
- FDA Approves UCB’s BIMZELX for the Treatment of Adults with Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-ucbs-bimzelx-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis/2462079/The U.S. Food and Drug Administration (FDA) has approved BIMZELX (bimekizumab-bkzx) for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Bimekizumab is the first and only approved psoriasis treatment designed to selectively i…
- IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanomahttps://practicaldermatology.com/news/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma/2462076/IDEAYA Biosciences, Inc. is initiating of a Phase 2 expansion of the darovasertib and crizotinib combination in GNAQ/11 metastatic cutaneous melanoma. There are currently no U.S Food and Drug Administration-approved therapies for this genetically-defined patient population. Darovasertib (IDE196) …
- AI in Action: Newest AI Boasts 100% Success Rate in Spotting Melanomashttps://practicaldermatology.com/news/newest-ai-boasts-100-success-rate-in-spotting-melanomas/2462072/The latest artificial intelligence (AI) software reached a 100% detection rate for melanoma, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin. The study assessed 22,356 patients with suspected skin cancers over a 2.5-year period. As …
- Delgocitinib Cream Soothes Moderate to Severe Chronic Hand Eczemahttps://practicaldermatology.com/news/delgocitinib-cream-soothes-moderate-to-severe-chronic-hand-eczema/2462071/Delgocitinib cream produced statistically significant improvements in both patient- and clinician-reported efficacy outcomes in adults with moderate to severe chronic hand eczema (CHE) compared to cream vehicle, according to results from the DELTA 2 trial presented at the European Academy of Dermat…
- Sotyktu Demonstrates Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque PsOhttps://practicaldermatology.com/news/sotyktu-demonstrates-durable-efficacy-and-consistent-safety-for-up-to-three-years-in-moderate-to-severe-plaque-pso/2462066/Bristol Myers Squibb’s Sotyktu (deucravacitinib) shows durable efficacy and consistent safety for up to three years in people with moderate-to-severe plaque psoriasis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin, Germany. Sotykt…
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Dermatology…
- Topical NFX-179 Inhibits MEK Activity, May Prevents SCChttps://practicaldermatology.com/news/topical-nfx-179-inhibits-mek-activity-may-prevents-scc/2462063/Topical NFX-179 may prevent the development of cutaneous squamous cell carcinoma in pre-clinical models, according to a new article published in Science Translational Medicine. “Our previous work showed that the canonical mitogen-activated protein kinase (MAPK) signaling pathway is important for t…